Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational ...

The proportion of adults in the US taking GLP-1 medications for weight loss has reached a record high of about 40 million people.

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly recognised for benefits beyond glycaemic ...

Patricia Louis is a content editor and social media strategist with a strong background in journalism, public relations and business. As the organic social media editor, she oversees and develops ...

Losing weight is best done with medical supervision. GLP-3s are investigational, potent weight-loss drugs targeting multiple hormone receptors. Side effects can be strong; medical supervision is ...

No difference in insulin discontinuation rates seen among three glucose-lowering classes ...

People searching for an affordable way to lose weight with a GLP-1 drug may come across products marketed as “GLP-1 patches” online. They’re advertised as helping to reduce cravings, control appetite ...

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set as demand for obesity therapeutics keeps ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of metabolic conditions such as obesity and diabetes. In addition to their weight loss benefits, these drugs also ...